PMID- 33816452
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210406
IS  - 2296-4185 (Print)
IS  - 2296-4185 (Electronic)
IS  - 2296-4185 (Linking)
VI  - 9
DP  - 2021
TI  - Possible Implications for Improved Osteogenesis? The Combination of Platelet-Rich 
      Fibrin With Different Bone Substitute Materials.
PG  - 640053
LID - 10.3389/fbioe.2021.640053 [doi]
LID - 640053
AB  - Bone substitute materials (BSM) are widely used in oral regeneration, but 
      sufficient angiogenesis is crucial for osteogenesis. The combination of BSM with 
      autologous thrombocyte concentrations such as platelet-rich fibrin (PRF) may 
      represent a clinical approach to overcome this limitation. This study analyzes 
      the early influence on osteoblast (HOB) in vitro. Here, four different BSM 
      (allogeneic, alloplastic, and two of xenogeneic origin) were combined with PRF. 
      After the incubation with osteoblasts for 24 h, cell viability, migration, and 
      proliferation were assessed. Next, marker of proliferation, migration, and 
      differentiation were evaluated on gene and protein levels in comparison to the 
      native BSM and osteoblast alone. Addition of PRF increased viability for both the 
      xenogeneic BSM (p = 0.0008, p = 0.032, respectively) in comparison to HOB and vs. 
      native BSM (p = 0.008), and led to a tendency for increased cell proliferation 
      and migration for all BSM (each p > 0.05). On gene basis, allogeneic and 
      alloplastic BSM displayed a significantly increased RUNX2 expression (each p = 
      0.050). Expression of alkaline phosphatase for alloplastic (p = 0.050) and 
      collagen-1 for xenogeneic BSM (p = 0.05) were significantly increased in 
      combination with PRF. In addition, bone morphogenic protein was expressed 
      significantly higher when xenogeneic material was combined with PRF in comparison 
      to HOB alone (each p = 0.05). In summary, the combination of PRF with different 
      BSM increases initial viability and may influence early proliferation and 
      migration potential of osteoblast via RUNX2, alkaline phosphatase, collagen, and 
      BMP2 especially in combination with alloplastic and xenogeneic BSM. 
      Biofunctionalization of BSM using PRF might improve osteogenesis and extend the 
      range of indications.
CI  - Copyright (c) 2021 Blatt, Thiem, Kyyak, Pabst, Al-Nawas and Kammerer.
FAU - Blatt, Sebastian
AU  - Blatt S
AD  - Department of Oral and Maxillofacial Surgery, University Medical Center, Johannes 
      Gutenberg University Mainz, Mainz, Germany.
AD  - Platform for Biomaterial Research, BiomaTiCS Group, University Medical Center, 
      Johannes Gutenberg University Mainz, Mainz, Germany.
FAU - Thiem, Daniel G E
AU  - Thiem DGE
AD  - Department of Oral and Maxillofacial Surgery, University Medical Center, Johannes 
      Gutenberg University Mainz, Mainz, Germany.
FAU - Kyyak, Solomiya
AU  - Kyyak S
AD  - Department of Oral and Maxillofacial Surgery, University Medical Center, Johannes 
      Gutenberg University Mainz, Mainz, Germany.
FAU - Pabst, Andreas
AU  - Pabst A
AD  - Department of Oral and Maxillofacial Surgery, Federal Armed Forces Hospital, 
      Koblenz, Germany.
FAU - Al-Nawas, Bilal
AU  - Al-Nawas B
AD  - Department of Oral and Maxillofacial Surgery, University Medical Center, Johannes 
      Gutenberg University Mainz, Mainz, Germany.
FAU - Kammerer, Peer W
AU  - Kammerer PW
AD  - Department of Oral and Maxillofacial Surgery, University Medical Center, Johannes 
      Gutenberg University Mainz, Mainz, Germany.
LA  - eng
PT  - Journal Article
DEP - 20210316
PL  - Switzerland
TA  - Front Bioeng Biotechnol
JT  - Frontiers in bioengineering and biotechnology
JID - 101632513
PMC - PMC8010662
OTO - NOTNLM
OT  - allograft
OT  - bone substitute
OT  - oral regeneration
OT  - osteoblast
OT  - platelet-rich fibrin
OT  - tissue engineering
OT  - xenograft
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/04/06 06:00
MHDA- 2021/04/06 06:01
PMCR- 2021/01/01
CRDT- 2021/04/05 06:09
PHST- 2020/12/10 00:00 [received]
PHST- 2021/02/22 00:00 [accepted]
PHST- 2021/04/05 06:09 [entrez]
PHST- 2021/04/06 06:00 [pubmed]
PHST- 2021/04/06 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fbioe.2021.640053 [doi]
PST - epublish
SO  - Front Bioeng Biotechnol. 2021 Mar 16;9:640053. doi: 10.3389/fbioe.2021.640053. 
      eCollection 2021.